NCT06344338 Application of tDCS Stimulation in Controlling Refractory Status Epilepticus
| NCT ID | NCT06344338 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Refractory Status Epilepticus |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-04-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus
Eligibility Criteria
Inclusion Criteria: * Age between 14 and 80 year-old with Gender unlimited, * Suitable for EEG monitoring; * Clinical diagnosis of Refractory status epilepticus (status epilepticus that cannot be controlled by two types of antiepileptic drugs and at least one anesthetic); * Informed consent to participate in this study was obtained from the participants or their surrogates Exclusion Criteria: * Unstable vital signs (systolic blood pressure\<90mmHg, heart rate\<60 beats/min, pulse oxygen saturation\<90%); * Having severe skull injury/defect or medical equipment implanted in the head; * Pregnancy; * With any implantable electronic instrument (including pacemakers, vagus nerve stimulators) or metal implanted devices.
Contact & Investigator
research centre of Xuanwu hospital Capital Medical University
✉ liugangqingyi@sina.com📞 +8601083198899
Weibi Chen, Dr
STUDY DIRECTOR
Xuanwu Hospital, Beijing
Frequently Asked Questions
Who can join the NCT06344338 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 80 Years, studying Refractory Status Epilepticus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06344338 currently recruiting?
Yes, NCT06344338 is actively recruiting participants. Contact the research team at liugangqingyi@sina.com for enrollment information.
Where is the NCT06344338 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06344338 clinical trial?
NCT06344338 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Weibi Chen, Dr at Xuanwu Hospital, Beijing. The trial plans to enroll 32 participants.